Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?

References

• Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5264):1394–1399. doi:10.1126/science.108595212730500
   PubMed Web of Science ®Google Scholar
• Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278–280. doi:10.1111/tmi.1338332052514
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-732015507
   PubMed Web of Science ®Google Scholar
• GISAID Global Initiative on Sharing All Influenza Data. Phylogeny of SARS-like betacoronaviruses including novelcoronavirus (nCoV). Available from: https://nextstrain.org/groups/blab/sars-like-cov.
   Google Scholar
• Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. doi:10.1016/S0140-6736(20)30185-931986257
   PubMed Web of Science ®Google Scholar
• Manocha S, Walley KR, Russell JA. Severe acute respiratory distress syndrome (SARS): a critical care perspective. Crit Care Med. 2003;31(11):2684–2692. doi:10.1097/01.CCM.0000091929.51288.5F14605542
   PubMed Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi:10.1056/NEJMc200146832003551
   PubMed Web of Science ®Google Scholar
• Cheng ZJ, Shan J. Novel coronavirus: where we are and what we know. Infection. 2019;2020(48):155–163. doi:10.1007/s15010-020-01401-y
   Web of Science ®Google Scholar
• Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun. 2004;314(1):235–241. doi:10.1016/j.bbrc.2003.12.08114715271
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi:10.1038/nature0214514647384
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. doi:10.1126/science.abb276232132184
   PubMed Web of Science ®Google Scholar
• Buscarini E, Manfredi G, Brambilla G, et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut. 2020;69:1547–1548. doi:10.1136/gutjnl-2020-32143432409587
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• Chen F, Liu ZS, Zhang FR, et al. [First case of severe childhood novel coronavirus pneumonia in China]. Zhonghua Er Ke Za Zhi. 2020;58:E005. doi:10.3760/cma.j.issn.0578-1310.2020.0005. [in Chinese.].32045966
   PubMedGoogle Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-732007143
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-032192578
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102. doi:10.1093/ofid/ofaa10232258207
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252. doi:10.1136/thorax.2003.01265814985565
   PubMed Web of Science ®Google Scholar
• Stower H. Lopinavir–ritonavir in severe COVID-19. Nat Med. 2020;26(4):465. doi:10.1038/s41591-020-0849-9
   Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30e31. doi:10.1016/S0140-6736(20)30304-432032529
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81:318–356. doi:10.1016/j.jinf.2020.04.017
   PubMed Web of Science ®Google Scholar
• Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol. 2008;8(4):259–268. doi:10.1038/nri227618340344
   PubMed Web of Science ®Google Scholar
• Maghazachi AA, Al-Aoukaty A. Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer. FASEB J. 1998;12(11):913–924. doi:10.1096/fasebj.12.11.9139707163
   PubMed Web of Science ®Google Scholar
• Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163–194. doi:10.1146/annurev-immunol-032712-10000123298212
   PubMed Web of Science ®Google Scholar
• Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–258. doi:10.1146/annurev-immunol-020711-07500523516982
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97(10):3146–3151. doi:10.1182/blood.v97.10.314611342442
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology. 2000;273(2):221–227. doi:10.1006/viro.2000.044210915592
   PubMed Web of Science ®Google Scholar
• Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189–220. doi:10.1146/annurev.immunol.17.1.18910358757
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. doi:10.1038/ni158218425107
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol. 2005;5(2):112–124. doi:10.1038/nri154915688039
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640. doi:10.1016/s1471-4906(01)02060-911698225
   PubMed Web of Science ®Google Scholar
• Maghazachi AA. Compartmentalization of human natural killer cells. Mol Immunol. 2005;42(4):523–529. doi:10.1016/j.molimm.2004.07.03615607808
   PubMed Web of Science ®Google Scholar
• Maghazachi AA. Insights into seven and single transmembrane-spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol Rev. 2005;57(3):339–357. doi:10.1124/pr.57.3.516109839
   PubMed Web of Science ®Google Scholar
• Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 1999;189(5):787–796. doi:10.1084/jem.189.5.78710049942
   PubMed Web of Science ®Google Scholar
• Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013;34(4):182–191. doi:10.1016/j.it.2013.01.00323414611
   PubMed Web of Science ®Google Scholar
• Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190(10):1505–1516. doi:10.1084/jem.190.10.150510562324
   PubMed Web of Science ®Google Scholar
• Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188(5):953–960. doi:10.1084/jem.188.5.9539730896
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Bakker ABH, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285(5428):730–732. doi:10.1126/science.285.5428.73010426994
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev. 2006;214:47–55. doi:10.1111/j.1600-065X.2006.00454.x17100875
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359–393. doi:10.1146/annurev.immunol.16.1.3599597134
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869. doi:10.3389/fimmu.2018.0186930150991
   PubMed Web of Science ®Google Scholar
• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645–657. doi:10.1038/nri304421869816
   PubMed Web of Science ®Google Scholar
• Lee S-H, Biron CA. Here today-not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur J Immunol. 2010;40(4):923–932. doi:10.1002/eji.20104030420209503
   PubMed Web of Science ®Google Scholar
• Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320(26):1731–1735. doi:10.1056/NEJM1989062932026052543925
   PubMed Web of Science ®Google Scholar
• Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011;3(3):274–279. doi:10.1159/00032417621411975
   PubMed Web of Science ®Google Scholar
• Elemam NM, Mekky RY, El-Ekiaby NM, et al. Repressing PU.1 by miR-29a in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. Hum Immunol. 2015;76(9):687–694. doi:10.1016/j.humimm.2015.09.02126429314
   PubMed Web of Science ®Google Scholar
• Orange Jordan S. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 2002;4(15):1545–1558. doi:10.1016/s1286-4579(02)00038-212505527
   PubMed Web of Science ®Google Scholar
• Yoon JC, Yang CM, Song Y, Lee JM. Natural killer cells in hepatitis C: current progress. World J Gastroenterol. 2016;22(4):1449–1460. doi:10.3748/wjg.v22.i4.144926819513
   PubMed Web of Science ®Google Scholar
• Arase H, Lanier LL. Specific recognition of virus-infected cells by paired NK receptors. Rev Med Virol. 2004;14(2):83–93. doi:10.1002/rmv.42215027001
   PubMed Web of Science ®Google Scholar
• Scalzo AA, Yokoyama WM. Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr Top Microbiol Immunol. 2008;321:101–122. doi:10.1007/978-3-540-75203-5_518727489
   PubMed Web of Science ®Google Scholar
• Hammer Q, Rückert T, Romagnani C. Natural killer cell specificity for viral infections. Nat Immunol. 2018;19(8):800–808. doi:10.1038/s41590-018-0163-630026479
   PubMed Web of Science ®Google Scholar
• Lam VC, Lanier LL. NK cells in host responses to viral infections. Curr Opin Immunol. 2017;44:43–51. doi:10.1016/j.coi.2016.11.00327984782
   PubMed Web of Science ®Google Scholar
• van Erp EA, van Kampen MR, van Kasteren PB, de Wit J. Viral infection of human natural killer cells. Viruses. 2019;11(3):243. doi:10.3390/v11030243
   Web of Science ®Google Scholar
• Guimei MM, Barqawi HJ, Dash NR, Maghazachi AA. Sepsis-the dilemma continues. MOJ Immunol. 2016;4(3):00125. doi:10.15406/moji.2016.04.00125
   Google Scholar
• Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir Res. 2017;137:82–92. doi:10.1016/j.antiviral.2016.11.00627840203
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang XM, Li SR, et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun. 2019;10(1):1507. doi:10.1038/s41467-019-09212-y30944315
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi:10.1038/s41423-020-0402-232203188
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718. doi:10.1126/science.abc602732661059
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294. doi:10.1016/s0140-6736(03)13973-612892961
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020.10243332113704
   PubMed Web of Science ®Google Scholar
• Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762–1769. doi:10.1093/infdis/jiaa15032227123
   PubMed Web of Science ®Google Scholar
• Cui W, Fan Y, Wu W, Zhang F, Wang JY, Ni AP. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37(6):857–859. doi:10.1086/37858712955652
   PubMed Web of Science ®Google Scholar
• He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9(6):323–330. doi:10.1016/j.ijid.2004.07.01416095942
   PubMed Web of Science ®Google Scholar
• National Research Project for Sars BG. The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am J Clin Pathol. 2004;121(4):507–511. doi:10.1309/WPK7-Y2XK-NF4C-BF3R.15080302
   PubMed Web of Science ®Google Scholar
• Osman MS, van Eeden C, Cohen Tervaert JW. Fatal COVID-19 infections: is NK cell dysfunction a link with autoimmune HLH? Autoimmun Rev. 2020;19(7):102561. doi:10.1016/j.autrev.2020.10256132376401
   PubMed Web of Science ®Google Scholar
• Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy. Available from: https://www.geekwire.com/2020/celularity-infectious-disease-research-institute-win-fdas-ok-try-covid-19-cell-therapy. Accessed 2020.
   Google Scholar
• Giuliani-promoted COVID-19 therapy from Celularity nabs FDA speedy trial start. Available from: https://www.fiercebiotech.com/biotech/rudy-giuliani-backed-covid-19-therapy-from-celularity-nabs-fda-speedy-trial-start. Accessed 2020.
   Google Scholar
• Han J, Chu J, Keung Chan W, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep. 2015;5:11483. doi:10.1038/srep1148326155832
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553. doi:10.1056/NEJMoa191060732023374
   PubMed Web of Science ®Google Scholar
• Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175–180. doi:10.1016/j.canlet.2019.11.03331790761
   PubMed Web of Science ®Google Scholar
• Market M, Angka L, Martel AB, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol. 2020;11:1512. doi:10.3389/fimmu.2020.0151232655581
   PubMed Web of Science ®Google Scholar
• Hachim MY, Elemam NM, Maghazachi AA. The beneficial and debilitating effects of environmental and microbial toxins, drugs, organic solvents and heavy metals on the onset and progression of multiple sclerosis. Toxins. 2019;11(3):147. doi:10.3390/toxins11030147
   PubMed Web of Science ®Google Scholar
• Caprariello AV, Rogers JA, Morgan ML, et al. Biochemically altered myelin triggers autoimmune demyelination. Proc Natl Acad Sci USA. 2018;115(21):5528–5533. doi:10.1073/pnas.172111511529728463
   PubMed Web of Science ®Google Scholar
• Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85(3):299–302. doi:10.1016/s0092-8674(00)81107-18616884
   PubMed Web of Science ®Google Scholar
• Maghazachi AA. Role of natural killer cells in multiple sclerosis. ISRN Immunol. 2012;2012:1–14. doi:10.5402/2012/795075
   Google Scholar
• Maghazachi AA. On the role of natural killer cells in neurodegenerative diseases. Toxins. 2013;5(2):363–375. doi:10.3390/toxins502036323430541
   PubMed Web of Science ®Google Scholar
• Hestvik AL. The double-edged sword of autoimmunity: lessons from multiple sclerosis. Toxins. 2010;2(4):856–877. doi:10.3390/toxins204085622069614
   PubMed Web of Science ®Google Scholar
• Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(1):1–10. doi:10.22074/cellj.2016.4867
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46(4):907–911. doi:10.1212/wnl.46.4.9078780061
   PubMed Web of Science ®Google Scholar
• Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006–1010. doi:10.1212/wnl.59.7.100612370453
   PubMed Web of Science ®Google Scholar
• Gadoth N. Multiple sclerosis in children. Brain Dev. 2003;25(4):229–232. doi:10.1016/s0387-7604(03)00035-412767451
   PubMed Web of Science ®Google Scholar
• Förster M, Küry P, Aktas O, et al. Managing risks with immune therapies in multiple sclerosis. Drug Saf. 2019;42(5):633–647. doi:10.1007/s40264-018-0782-830607830
   PubMed Web of Science ®Google Scholar
• Al-Jaderi Z, Maghazachi AA. Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases. Front Immunol. 2016;7:278. doi:10.3389/fimmu.2016.0027827499754
   PubMed Web of Science ®Google Scholar
• Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2010;221(12):7–14. doi:10.1016/j.jneuroim.2009.10.01519931190
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Münz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis? Brain. 2008;131(Pt 7)):1681–1683. doi:10.1093/brain/awn13218586760
   PubMed Web of Science ®Google Scholar
• Mimpen M, Smolders J, Hupperts R, Damoiseaux J. Natural killer cells in multiple sclerosis: a review. Immunol Lett. 2020;222:1–11. doi:10.1016/j.imlet.2020.02.01232113900
   PubMed Web of Science ®Google Scholar
• Morandi B, Bramanti P, Bonaccorsi I, et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res. 2008;57(1):1–5. doi:10.1016/j.phrs.2007.11.00318182304
   PubMed Web of Science ®Google Scholar
• Leavenworth JW, Schellack C, Kim HJ, Lu L, Spee P, Cantor H. Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab’)2. Proc Natl Acad Sci USA. 2010;107(6):2562–2567. doi:10.1073/pnas.091473210720133787
   PubMed Web of Science ®Google Scholar
• Hao J, Liu R, Piao W, et al. Central nervous system (CNS)–resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 2010;207(9):1907–1921. doi:10.1084/jem.2009274920696699
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Kohyama K, Aikawa Y, et al. Role of natural killer cells and TCRγ δ T cells in acute autoimmune encephalomyelitis. Eur J Immunol. 1998;28(5):1681–1688. doi:10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T9603475
   PubMed Web of Science ®Google Scholar
• Segal BM. The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol. 2007;191(12):2–7. doi:10.1016/j.jneuroim.2007.09.00617904646
   PubMed Web of Science ®Google Scholar
• Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain. 2004;127(Pt 9):1917–1927. doi:10.1093/brain/awh21915229129
   PubMed Web of Science ®Google Scholar
• Liu Q, Sanai N, Jin WN, La-Cava A, Van-Kaer L, Shi FD. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 2016;19(2):243–252. doi:10.1038/nn.421126752157
   PubMed Web of Science ®Google Scholar
• Lepennetier G, Hracsko Z, Unger M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. J Neuroinflammation. 2019;16(1):219. doi:10.1186/s12974-019-1601-631727097
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Rünzi A, et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci USA. 2016;113(21):E2973E2982. doi:10.1073/pnas.152492411327162345
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martín E, Picón C, Costa-Frossard L, et al. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol. 2015;180(2):243–249. doi:10.1111/cei.1258025565222
   PubMed Web of Science ®Google Scholar
• Pandya AD, Al-Jaderi Z, Høglund RA, et al. Identification of human NK17/NK1 cells. PLoS One. 2011;6(10):e26780. doi:10.1371/journal.pone.002678022039549
   PubMed Web of Science ®Google Scholar
• Elemam NM, Hannawi S, Maghazachi AA. Innate lymphoid cells (ILCs) as mediators of inflammation, release of cytokines and lytic molecules. Toxins. 2017;9(12):E398. doi:10.3390/toxins912039829232860
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Wiendl H, et al. Regulatory functions of natural killer cells in multiple sclerosis. Front Immunol. 2016;7:606. doi:10.3389/fimmu.2016.0060628066417
   PubMed Web of Science ®Google Scholar
• Durrenberger PF, Webb LV, Sim MJ, et al. Expression in white matter lesions in multiple sclerosis. Immunology. 2012;137(4):317–325. doi:10.1111/imm.1201223039207
   PubMed Web of Science ®Google Scholar
• Laroni A, Uccelli A. CD56bright natural killer cells: a possible biomarker of different treatments in multiple sclerosis. J Clin Med. 2020;9:5. doi:10.3390/jcm9051450
   Web of Science ®Google Scholar
• Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA. 2004;101:14593–14598. doi:10.1073/pnas.040488710115371592
   PubMed Web of Science ®Google Scholar
• Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011;235(12):9–17. doi:10.1016/j.jneuroim.2011.01.00921402415
   PubMed Web of Science ®Google Scholar
• Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127(Pt 6):1370–1378. doi:10.1093/brain/awh16315090474
   PubMed Web of Science ®Google Scholar
• Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci. 2009;66(8):1446–1456. doi:10.1007/s00018-009-8726-119277466
   PubMed Web of Science ®Google Scholar
• Høglund RA, Holmøy T, Harbo HF, Maghazachi AA. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA). PLoS One. 2013;8(4):e62237. doi:10.1371/journal.pone.006223723614042
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105(7):967–976. doi:10.1172/JCI897010749576
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172(11):7144–7153. doi:10.4049/jimmunol.172.11.714415153538
   PubMed Web of Science ®Google Scholar
• Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol. 2009;7(1):60–64. doi:10.2174/15701590978760278819721818
   PubMed Web of Science ®Google Scholar
• Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8(1):20–30. doi:10.1177/175628561456415225584071
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3)):678–692. doi:10.1093/brain/awq38621354971
   PubMed Web of Science ®Google Scholar
• Marastoni D, Buriani A, Pisani AI, et al. Increased NK cell count in multiple sclerosis patients treated with dimethyl fumarate: a 2-year longitudinal study. Front Immunol. 2019;10:1666. doi:10.3389/fimmu.2019.0166631379857
   PubMed Web of Science ®Google Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26(9):2067–2074. doi:10.1002/eji.18302609168814248
   PubMed Web of Science ®Google Scholar
• Al-Jaderi Z, Maghazachi AA. Vitamin D3 and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis. Toxins. 2015;7(11):4730–4744. doi:10.3390/toxins711473026580651
   PubMed Web of Science ®Google Scholar
• Elemam NM, Al-Jaderi Z, Hachim MY, Maghazachi AA. HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells. Cancer Immunol Immunother. 2019;68(6):883–895. doi:10.1007/s00262-019-02319-730847498
   PubMed Web of Science ®Google Scholar
• Vego H, Sand KL, Høglund RA, et al. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol. 2016;13(1):57–64. doi:10.1038/cmi.2014.11425435072
   PubMed Web of Science ®Google Scholar
• Maghazachi AA, Sand KL, Al-Jaderi Z. Glatiramer acetate, dimethyl fumarate, and monomethyl fumarate upregulate the expression of CCR10 on the surface of natural killer cells and enhance their chemotaxis and cytotoxicity. Front Immunol. 2016;7:437. doi:10.3389/fimmu.2016.0043727807435
   PubMed Web of Science ®Google Scholar
• Mohan T, Deng L, Wang BZ. CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol. 2017;51:165–170. doi:10.1016/j.intimp.2017.08.01228843907
   PubMed Web of Science ®Google Scholar
• Muhammad JS, Jayakumar MN, Elemam NM, et al. Gasdermin D hypermethylation inhibits pyroptosis and LPS-induced IL-1β release from NK92 cells. Immunotargets Ther. 2019;8:29–41. doi:10.2147/ITT.S21986731687364
   PubMed Web of Science ®Google Scholar
• Smith MD, Calabresi PA, Bhargava P. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. Eur J Immunol. 2018;48(2):380–383. doi:10.1002/eji.20174727729108094
   PubMed Web of Science ®Google Scholar
• Medina S, Villarrubia N, Sainz de la Maza S, et al. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. Mult Scler. 2018;24(10):1317–1327. doi:10.1177/135245851771708828653862
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol. 2007;61(6):504–513. doi:10.1002/ana.2114117492755
   PubMed Web of Science ®Google Scholar
• Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87(3):1103–1107. doi:10.1172/JCI1150721705564
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA. 1996;93(15):7861–7864. doi:10.1073/pnas.93.15.78618755567
   PubMed Web of Science ®Google Scholar
• Burton JM, Kimball S, Vieth R, et al. A Phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–1859. doi:10.1212/WNL.0b013e3181e1cec220427749
   PubMed Web of Science ®Google Scholar
• Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019;93(20):e1906e1916. doi:10.1212/wnl.000000000000844531594857
   PubMed Web of Science ®Google Scholar
• Rinaldi AO, Sanseverino I, Purificato C, et al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins. 2015;7(1):129–137. doi:10.3390/toxins701012925590278
   PubMed Web of Science ®Google Scholar
• Al-Jaderi Z, Maghazachi AA. Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins. 2013;5(11):1932–1947. doi:10.3390/toxins511193224169587
   PubMed Web of Science ®Google Scholar
• Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modulating effects of high dose vitamin d3 supplementation in multiple sclerosis. PLoS One. 2010;5(12):e15235. doi:10.1371/journal.pone.001523521179201
   PubMed Web of Science ®Google Scholar
• Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009;4(8):e6635. doi:10.1371/journal.pone.000663519675671
   PubMed Web of Science ®Google Scholar
• Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a Phase II extension study. Neurology. 2009;72(1):73–79. doi:10.1212/01.wnl.0000338569.32367.3d19122034
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–1140. doi:10.1056/NEJMoa05264316971719
   PubMed Web of Science ®Google Scholar
• Rolin J, Sand KL, Knudsen E, Maghazachi AA. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010;59(4):575–586. doi:10.1007/s00262-009-0775-719823820
   PubMed Web of Science ®Google Scholar
• Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci. 2007;28(3):121–126. doi:10.1007/s10072-007-0803-317603762
   PubMed Web of Science ®Google Scholar
• Martínez-Rodríguez JE, López-Botet M, Munteis E, et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol. 2011;141(3):348–356. doi:10.1016/j.clim.2011.09.00621992960
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K. Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up. Front Neurol. 2018;9:1071. doi:10.3389/fneur.2018.0107130581413
   PubMed Web of Science ®Google Scholar
• Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83(1):13–26. doi:10.1002/ana.2511929244240
   PubMed Web of Science ®Google Scholar